NO152049C - Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol - Google Patents

Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol

Info

Publication number
NO152049C
NO152049C NO782127A NO782127A NO152049C NO 152049 C NO152049 C NO 152049C NO 782127 A NO782127 A NO 782127A NO 782127 A NO782127 A NO 782127A NO 152049 C NO152049 C NO 152049C
Authority
NO
Norway
Prior art keywords
tetrahydroisocsazolo
pyridin
preparing
pharmaceutical use
use compound
Prior art date
Application number
NO782127A
Other languages
English (en)
Other versions
NO152049B (no
NO782127L (no
Inventor
Povl Krogsgaard-Larsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO782127L publication Critical patent/NO782127L/no
Publication of NO152049B publication Critical patent/NO152049B/no
Publication of NO152049C publication Critical patent/NO152049C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
NO782127A 1977-06-20 1978-06-19 Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol NO152049C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (3)

Publication Number Publication Date
NO782127L NO782127L (no) 1978-12-21
NO152049B NO152049B (no) 1985-04-15
NO152049C true NO152049C (no) 1985-07-24

Family

ID=10232513

Family Applications (3)

Application Number Title Priority Date Filing Date
NO782128A NO782128L (no) 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater
NO782127A NO152049C (no) 1977-06-20 1978-06-19 Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol
NO792839A NO792839L (no) 1977-06-20 1979-09-03 Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO782128A NO782128L (no) 1977-06-20 1978-06-19 Fremgangsmaate for fremstilling av fysiologisk aktive isonikotinsyrederivater

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO792839A NO792839L (no) 1977-06-20 1979-09-03 Mellomprodukt for anvendelse ved fremstilling av fysiologisk aktive isonikotinsyrederivater

Country Status (14)

Country Link
US (2) US4278676A (no)
EP (4) EP0028017A1 (no)
JP (2) JPS5436290A (no)
AT (1) AT368505B (no)
AU (2) AU3724478A (no)
CA (1) CA1107736A (no)
DK (2) DK270378A (no)
ES (2) ES470912A1 (no)
FI (2) FI64376C (no)
IE (1) IE47200B1 (no)
IT (2) IT1159739B (no)
NO (3) NO782128L (no)
NZ (1) NZ187615A (no)
ZA (2) ZA783492B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (en) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinamide derivatives, a process for producing the same and a pharmaceutical composition comprising the same
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
WO2004112786A2 (en) 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20050176680A1 (en) * 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
WO2005063297A2 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
DE602005018763D1 (de) * 2004-02-18 2010-02-25 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP2292222A1 (en) 2005-01-28 2011-03-09 H. Lundbeck A/S Polymorphic Forms of a GABAA Agonist
US20080262029A1 (en) * 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
HUE055400T2 (hu) 2014-06-06 2021-11-29 Ovid Therapeutics Inc Módszerek a tónusos gátlás növelésére és az Angelman-szindróma kezelésére
SI3274331T1 (sl) * 2015-03-24 2020-08-31 H. Lundbeck A/S Izdelava 4,5,6,7-tetrahidroizozaksolo (5,4-C)piridin-3-ol
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
IL305342A (en) * 2015-07-17 2023-10-01 Ovid Therapeutics Inc Methods for treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
CN111201022A (zh) 2017-08-04 2020-05-26 奥维德医疗公司 加波沙朵在治疗糖尿病及相关状况中的用途
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
SG11202105358RA (en) 2018-11-21 2021-06-29 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
CA3182508A1 (en) 2020-05-20 2021-11-25 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-(n-乙酰基)哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
FI64376C (fi) 1983-11-10
IT7868449A0 (it) 1978-06-20
NO792839L (no) 1978-12-21
EP0028017A1 (en) 1981-05-06
AU521040B2 (en) 1982-03-11
JPS5436275A (en) 1979-03-16
CA1107736A (en) 1981-08-25
EP0000338B1 (en) 1981-11-25
ZA783493B (en) 1979-06-27
US4278676A (en) 1981-07-14
ES470913A1 (es) 1979-02-01
EP0000338A3 (en) 1979-06-27
IE47200B1 (en) 1984-01-11
DK270378A (da) 1978-12-21
EP0000338A2 (en) 1979-01-24
AU3729878A (en) 1980-01-03
FI781954A (fi) 1978-12-21
DK270278A (da) 1978-12-21
IT7868450A0 (it) 1978-06-20
ATA448678A (de) 1982-02-15
IT1159739B (it) 1987-03-04
NO152049B (no) 1985-04-15
FI781955A (fi) 1978-12-21
US4301287A (en) 1981-11-17
AT368505B (de) 1982-10-25
IE781234L (en) 1978-12-20
JPS5436290A (en) 1979-03-16
EP0027279A1 (en) 1981-04-22
NZ187615A (en) 1981-12-15
ZA783492B (en) 1979-06-27
NO782128L (no) 1978-12-21
AU3724478A (en) 1980-01-03
EP0000167A1 (en) 1979-01-10
FI64376B (fi) 1983-07-29
ES470912A1 (es) 1979-02-01
NO782127L (no) 1978-12-21

Similar Documents

Publication Publication Date Title
NO152049C (no) Analogifremgangsmaate for fremstilling av den farmasoeytisk anvendelige forbindelse 4,5,6,7-tetrahydroisoksazolo (5,4-c)pyridin-3-ol
NO154918C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
IT7849473A0 (it) Procedimento per preparare 1,2 polibutadiene
AR224095A1 (es) Procedimiento de preparacion de nuevos derivados de ditiol-1,2 tiona-3
RO75777A (ro) Procedeu pentru prepararea unor 1,2-benzizotiazolin-3-one
SE7808059L (sv) Forfarande for framstellning av 1,2,4-triazin-5-on-derivat
SE7604475L (sv) Forfarande for framstellning av 1,1,1-triaryl-alkylaminer
RO82507A (ro) Procedeu pentru prepararea unor derivati ai acidului 1,2,3-tiadiazol-procedeu pentru prepararea unor derivati ai acidului 1,2,3-tiadiazol-5-carboxilic
RO77485A (ro) Procedeu pentru prepararea 1,2,3-tiadiazol-3-in-5-ilidenureelor
RO76721A (ro) Procedeu pentru prepararea 3.12.-hidroxi-4-fenil-cicloalcanonei
AR218498A1 (es) Procedimiento de preparacion de derivados de 1,3-difenoxipropan-2-ona
NO152645C (no) Fremgangsmaate for fremstilling av klordioksyd.
SE7804878L (sv) Forfarande for framstellning av 1,2-dikloretan
ES495819A0 (es) Procedimiento de preparar derivados 1,2,4-oxadiazolin-5-oni-cos
AR224501A1 (es) Procedimiento de preparacion de derivados de la tieno-(3,2-c)-piridina
NO147601C (no) Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse l-pyroglutamyl-l-histidyl-glycin
SE428922B (sv) Forfarande for framstellning av 13, 14-dihydro-11-dioxi-prostaglandiner
SE7802669L (sv) Forfarande for framstellning av 2,1,3-tiadiazin-4-on-2,2-dioxidderivat
IT1094983B (it) Procedimento per la preparazione di 3,5 di alogeno-aniline
ES494286A0 (es) Procedimiento de preparacion de nuevos derivados 1,1,2-tri- fenilpropanos y -propenos
ES491153A0 (es) Procedimiento de preparar derivados pirrolo(1,2-a)pirimidi- nicos
NO145135C (no) Analogifremgangsmaate ved fremstilling av den terapeutisk aktive forbindelse 3-cyan-n-(n,n-diemtylaminopropyl)-iminodibenzyl
NO144067C (no) Fremgangsmaate for fremstilling av di-n-propylacetonitril.
SE7608453L (sv) Forfarande for framstellning av 1,2,3,4-tetrahydroisokinoliner
RO85268A (ro) Procedeu pentru prepararea unor derivati de 1,2,4-oxadiazina